These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8477764)

  • 21. [Tissue pharmacokinetics of antibiotics. Theoretical bases and new pharmacological approaches].
    Bergogne-Bérézin E
    Presse Med; 1996 Mar 2-9; 25(8):399-406. PubMed ID: 8685188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives.
    de Velde F; Mouton JW; de Winter BCM; van Gelder T; Koch BCP
    Pharmacol Res; 2018 Aug; 134():280-288. PubMed ID: 30033398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibiotic exposure at the site of infection: principles and assessment of tissue penetration.
    Jager NGL; van Hest RM; Lipman J; Roberts JA; Cotta MO
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):623-634. PubMed ID: 31136211
    [No Abstract]   [Full Text] [Related]  

  • 25. Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections.
    Pea F
    Curr Opin Infect Dis; 2016 Apr; 29(2):153-9. PubMed ID: 26836376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.
    Pienaar E; Cilfone NA; Lin PL; Dartois V; Mattila JT; Butler JR; Flynn JL; Kirschner DE; Linderman JJ
    J Theor Biol; 2015 Feb; 367():166-179. PubMed ID: 25497475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Principles in the treatment of bacterial meningitis.
    Täuber MG; Sande MA
    Am J Med; 1984 May; 76(5A):224-30. PubMed ID: 6372474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Contribution of the experimental model of bacterial endocarditis].
    Carbon C
    Bull Acad Natl Med; 1995 Apr; 179(4):767-74; discussion 775-6. PubMed ID: 7648311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.
    Hyatt JM; McKinnon PS; Zimmer GS; Schentag JJ
    Clin Pharmacokinet; 1995 Feb; 28(2):143-60. PubMed ID: 7736689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.
    Scaglione F; Paraboni L
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):479-90. PubMed ID: 16771624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics and the relationship between in vitro and in vivo activity of antimicrobial agents.
    Gould IM
    J Chemother; 1997 May; 9 Suppl 1():74-83. PubMed ID: 9248965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relevance of various animal models of human infections to establish therapeutic equivalence of a generic product of piperacillin/tazobactam.
    Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2015 Feb; 45(2):161-7. PubMed ID: 25481459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of antimicrobials.
    Drusano GL
    Clin Infect Dis; 2007 Jul; 45 Suppl 1():S89-95. PubMed ID: 17582578
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial Pharmacokinetics and Pharmacodynamics.
    Jarrell AS; Kruer RM; Johnson D; Lipsett PA
    Surg Infect (Larchmt); 2015 Aug; 16(4):375-9. PubMed ID: 26207398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
    Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
    Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options).
    Payne KD; Das A; Ndiulor M; Hall RG
    Expert Rev Clin Pharmacol; 2018 Feb; 11(2):139-149. PubMed ID: 29186999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomes as carriers of antimicrobial agents or immunomodulatory agents in the treatment of infections.
    Bakker-Woudenberg IA; Lokerse AF; ten Kate MT; Melissen PM; van Vianen W; van Etten EW
    Eur J Clin Microbiol Infect Dis; 1993; 12 Suppl 1():S61-7. PubMed ID: 8477767
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Zhou YF; Tao MT; He YZ; Sun J; Liu YH; Liao XP
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of microdialysis for the assessment of fluoroquinolone pharmacokinetics in the clinical practice.
    Tomas A; Stilinović N; Sabo A; Tomić Z
    Eur J Pharm Sci; 2019 Apr; 131():230-242. PubMed ID: 30811969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.